Call for Abstracts
Note
All presentations in the APGCC × JGCA Joint Session are by invitation only, and abstract submissions are not open to the public.
Abstracts from overseas presenters will be accepted collectively through our co-hosted congress, JGCA2026.
Submitted abstracts will be officially recognized as part of the programs of both APGCC2026 and JGCA2026, and will be counted toward the official participation record of both congresses.
Abstract Submission Period
Abstracts for oral, poster
Wednesday, 9 July, 12:00 PM (JST) – Wednesday, 27 August, 12:00 PM (JST)
Abstract Submission
You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.
To change or update your registration information, please click the “Confirmation / Modification” button.
This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.
Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.
Presentation Style/Categories
Please select the most appropriate category for your presentation.
Main session style
Oral presentation
Main session category
Symposium
Frontline of New Drug Development – Expectations for Gastric Cancer
This session will discuss the latest trends and future prospects of drugs and seeds that are currently under development or may be developed for gastric cancer.
Cutting-Edge Robotic Surgery: The Next Frontier
Panel discussion
Present and future perspective of AI/Digital Pathology
Surgical Strategies in Reconstruction After Proximal Gastrectomy: Balancing Function and Safety
Workshop
Impact of AI on managing gastric cancer in endoscopy, pathology, and surgery
General Presentation style
Oral presentation, Poster presentation (Paper style)
If you are submitting a general abstract, we actively encourage Oral presentations and would be grateful if you would consider submitting one.
General Presentation category
1 | Epidemiology |
---|---|
2 | Molecular biology |
3 | Pathology |
4 | Genomics |
5 | Translational research |
6 | Biomarker |
7 | Tumor microenvironment |
8 | AI |
9 | Endoscopic therapy |
10 | Endoscopic diagnosis |
11 | Imaging diagnosis |
12 | H. pylori |
13 | Progression of gastric cancer |
14 | Rare metastasis / Micrometastasis |
15 | Intraoperative frozen section |
16 | Cancer stem cell |
17 | Clinical pathology |
18 | Prognostic factor |
19 | Precision medicine |
20 | Clinical study |
21 | Chemotherapy |
22 | Neoadjuvant chemotherapy |
23 | Adjuvant chemotherapy |
24 | Second-line chemotherapy |
25 | Third-line chemotherapy |
26 | Intraperitoneal chemotherapy |
27 | Molecular targeted therapy |
28 | Immunotherapy |
29 | Radiation therapy |
30 | conversion surgery |
31 | Surgery |
32 | Laparoscopic surgery |
33 | Robot surgery |
34 | Function-preserving surgery |
35 | Cytoreductive surgery |
36 | LECS |
37 | Surgical navigation |
38 | Postoperative functional assessment |
39 | Postgastrectomy syndrome |
40 | Perioperative management |
41 | Postoperative complications |
42 | ERAS |
43 | Navigation Surgery |
---|---|
44 | Peritoneal dissemination |
45 | CART |
46 | Stent placement |
47 | Liver metastasis |
48 | Recurrence |
49 | Early gastric cancer |
50 | Advanced gastric cancer |
51 | Scirrhous gastric cancer |
52 | Gastric stump carcinoma |
53 | Multiple gastric cancers |
54 | Gastric tube cancer |
55 | Esophago-gastric junction cancer |
56 | Gastric cancer in elderly patients |
57 | AFP-producing gastric cancer |
58 | EBV-related gastric cancer |
59 | Gastrointestinal stromal tumor |
60 | Malignant lymphoma |
61 | Gastric neuroendocrine tumor |
62 | Guidelines |
63 | Clinical pathway |
64 | Postoperative surveillance |
65 | Long-term survival case after chemotherapy |
66 | NST |
67 | Outcome |
68 | QOL assessment |
69 | Cachexia |
70 | Nutrition |
71 | Obesity |
72 | Case report |
73 | Japanese Classification of Gastric Carcinoma |
74 | Multidisciplinary treatment |
75 | Palliative therapy |
76 | Team approach |
77 | Patient Adovocacy |
78 | MDT conference |
79 | Medical cooperation |
80 | Oral care |
81 | EFTR |
82 | Oligometastasis |
83 | Others |
About the Best Poster Session
About the Poster Session for the Best Presentation The best poster abstracts will be selected from among the general abstract (poster) submissions at after a rigorous review process.
Abstract Acceptance or Rejection
Please note that the acceptance or rejection of abstracts, as well as the presentation format, is at the sole discretion of the Congress President.
Travel Grant
The Travel Grant will be awarded to abstracts recognized as outstanding.
The selection process is entirely entrusted to the discretion of the Congress President.
Abstract Submission
Language for abstract
English
Language for presentation
English
Language for presentation slides
English
The number of characters
Title: Up to 120 characters including spaces (approximately 20-24 words)
Abstract: Up to 2,000 characters including spaces (approximately 330-400 words)
* Please note that the abstract will be published as submitted. We kindly ask you to carefully check for any typographical or grammatical errors before submission.
Conflict of Interest Disclosure
The author is required to report applicable COI (Conflict of Interest) by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process.
Abstract Submission
You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.
To change or update your registration information, please click the “Confirmation / Modification” button.
This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.
Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.
Inquiries
Secretariat of the 98th Annual Meeting of the Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-98jgca[A]convention[D]co[D]jp( Please change [A] to @ and [D] to . )